TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9374341

Group type: EXPERIMENTAL
Intervention: Nalmefene (1 mg or 1 microg/kg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Naloxone (2 mg or 2 microg/kg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Nalmefene
Number of subjects: 8

Group type: COMPARATOR
Intervention: Naloxone
Number of subjects: 8
Study: 1586185

Group type: EXPERIMENTAL
Intervention: Bolus nasogastric feeding
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Continuous nasogastric feeding
Number of subjects: 43

Group type: COMPARATOR
Intervention: Transpyloric feeding
Number of subjects: 43
Study: 2883828

Group type: EXPERIMENTAL
Intervention: Temazepam 20 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Triazolam 0.25 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nitrazepam 5 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Flurazepam 15 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 28945649

Group type: EXPERIMENTAL
Intervention: Biotissue Cliradex (CD)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: OCuSOFT Lid Scrubs Plus (OP)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: NovaBay Avenova (NA)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: TheraTears Theralid (TT)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: OCuSOFT OUST Demodex Swabstix (ODS)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Bausch+Lomb Sensitive Eyes Plus saline
Number of subjects: 26
Study: 27323936

Group type: EXPERIMENTAL
Intervention: Metabolic profile at 4 months of age
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Metabolite concentrations
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Age at diagnosis using survival models
Number of subjects: 230
Study: 24836273

Group type: EXPERIMENTAL
Intervention: Radium-223 (50 kBq/kg, six intravenous injections, one every 4 weeks)
Number of subjects: 921

Group type: COMPARATOR
Intervention: Placebo (matching placebo)
Number of subjects: 921

Group type: EXPERIMENTAL
Intervention: Radium-223
Number of subjects: 921
Study: 22800506

Group type: EXPERIMENTAL
Intervention: CaPRA (intervention)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 50
Study: 20507387

Group type: COMPARATOR
Intervention: High-dose intravenous immunoglobulin (HD-IVIG) at a dosage of 400 mg/kg per day for 5 days as an adjuvant therapy with systemic steroid therapy and/or immunosuppressive agents.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-dose intravenous immunoglobulin (HD-IVIG)
Number of subjects: 0
Study: 18206732

Group type: EXPERIMENTAL
Intervention: Omeprazole (20 mg/day)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study: 15992641

Group type: EXPERIMENTAL
Intervention: Three-dimensional navigator-gated magnetic resonance imaging (MR)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: 16-slice multidetector row computed tomography (MDCT)
Number of subjects: 52
Study: 14688811

Group type: EXPERIMENTAL
Intervention: Telmisartan 80 mg
Number of subjects: 69

Group type: COMPARATOR
Intervention: Hydrochlorothiazide 25 mg
Number of subjects: 69
Study: 11301670

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 9164193

Group type: COMPARATOR
Intervention: Etoposide plus cisplatin (EP)
Number of subjects: 419

Group type: EXPERIMENTAL
Intervention: Bleomycin, etoposide, and cisplatin (BEP)
Number of subjects: 419

Group type: EXPERIMENTAL
Intervention: BEP
Number of subjects: 419
Study: 8426316

Group type: COMPARATOR
Intervention: Monofocal implant (Group 1)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Multifocal implant (Group 2)
Number of subjects: 50
Study: 3501902

Group type: EXPERIMENTAL
Intervention: Dipyridamole (DP) 75 mg and Acetylsalicylic acid (ASA) 325 mg thrice daily for 3 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo regimen identical to DP-ASA
Number of subjects: 0
Study: 31882240

Group type: EXPERIMENTAL
Intervention: Tibetan medicated bathing therapy in combination with conventional rehabilitation
Number of subjects: 444

Group type: COMPARATOR
Intervention: Conventional rehabilitation
Number of subjects: 444
Study: 29055624

Group type: EXPERIMENTAL
Intervention: Pegylated liposomal doxorubicin (PLD)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Capecitabine
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Geriatric assessment (GA)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Karnofsky Performance Status (KPS)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Cumulative illness rating scale‐geriatrics (CIRS‐G)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Glasgow prognostic score (GPS)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Prognostic inflammatory and nutritional index (PINI)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Instrumental activities of daily living (IADL) from GA
Number of subjects: 210
Study: 27865535

Group type: EXPERIMENTAL
Intervention: Intratympanic methylprednisolone (62.5 mg/mL)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intratympanic gentamicin (40 mg/mL)
Number of subjects: 60
Study: 25149995

Group type: EXPERIMENTAL
Intervention: Simvastatin (40 mg daily)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control (healthy subjects)
Number of subjects: 42
Study: 23006808

Group type: EXPERIMENTAL
Intervention: Formal auditory training (AT) for 8 weeks in APD and SLIa groups
Number of subjects: 30

Group type: COMPARATOR
Intervention: c-ABR with background noise
Number of subjects: 30

Group type: COMPARATOR
Intervention: c-ABR in silence
Number of subjects: 30

Group type: COMPARATOR
Intervention: Behavioral assessment of auditory processing
Number of subjects: 30
Study: 20863398

Group type: EXPERIMENTAL
Intervention: Iron supplement (IS) - 20 mg iron
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: Iron + folic acid supplement (IFS) - 12.5 mg iron
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: Multiple micronutrient supplement (MMS) - 10 mg iron
Number of subjects: 266

Group type: COMPARATOR
Intervention: Micronutrient-fortified complementary food (FCF) - 10 mg iron
Number of subjects: 266

Group type: COMPARATOR
Intervention: Zinc + iron + ascorbic acid fortified water (FW) - 6.7 mg iron
Number of subjects: 266
Study: 17766187

Group type: EXPERIMENTAL
Intervention: Educational Video Group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Documentation Group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 0
Study: 16624398

Group type: EXPERIMENTAL
Intervention: Teaching units on giving advice to stop smoking (3 units, 1 day each)
Number of subjects: 956

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 956
Study: 12916465

Group type: EXPERIMENTAL
Intervention: STI-571 (Imatinib)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multimodality treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Limb-sparing procedures
Number of subjects: 0
Study: 10812377

Group type: EXPERIMENTAL
Intervention: Low-fat condition
Number of subjects: 30

Group type: COMPARATOR
Intervention: Regular-fat condition
Number of subjects: 30
Study: 8979323

Group type: EXPERIMENTAL
Intervention: Specific, localized, exercise therapy
Number of subjects: 39

Group type: COMPARATOR
Intervention: Medical treatment only
Number of subjects: 39
Study: 1424856

Group type: EXPERIMENTAL
Intervention: Continuous bronchodilator treatment (salbutamol in the first year and ipratropium bromide in the second year)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Symptomatic bronchodilator treatment (salbutamol in the first year and ipratropium bromide in the second year)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Continuous bronchodilator treatment
Number of subjects: 144

Group type: COMPARATOR
Intervention: Symptomatic bronchodilator treatment
Number of subjects: 144
Study: 3874038

Group type: EXPERIMENTAL
Intervention: Sulindac sulfoxide (200 mg b.i.d.)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Sulindac sulfide (100 mg b.i.d.)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Aspirin (650 mg q.i.d.)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 31925845

Group type: EXPERIMENTAL
Intervention: Wet Group (stored in distilled water)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Dry Group (stored in a dry container)
Number of subjects: 40
Study: 29412167

Group type: EXPERIMENTAL
Intervention: Client-centered 'tune-up' intervention (1-hour therapy sessions, 3 times/week for 2 weeks at 6 months postdischarge)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Control group (same exposure to assessment)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Both groups (tune-up and control)
Number of subjects: 103
Study: 27375126

Group type: EXPERIMENTAL
Intervention: Universal door-to-door delivery of HIV testing and referral to prevention and treatment services with immediate offer of anti-retroviral treatment regardless of clinical status
Number of subjects: 52500

Group type: EXPERIMENTAL
Intervention: Universal door-to-door delivery of HIV testing and referral to prevention and treatment services with offer of treatment in-line with national guidelines
Number of subjects: 52500

Group type: COMPARATOR
Intervention: Standard-of-care control arm
Number of subjects: 52500
Study: 24807330

Group type: EXPERIMENTAL
Intervention: Indomethacin and antibiotics
Number of subjects: 53

Group type: COMPARATOR
Intervention: No perioperative prophylactic medications (Control)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Both groups (Indomethacin and antibiotics vs Control)
Number of subjects: 53
Study: 22143739

Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine
Number of subjects: 18

Group type: COMPARATOR
Intervention: 4% articaine
Number of subjects: 18
Study: 19740546

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Lithium
Number of subjects: 40
Study: 18279948

Group type: EXPERIMENTAL
Intervention: Probiotics (n=152)
Number of subjects: 298

Group type: COMPARATOR
Intervention: Placebo (n=144)
Number of subjects: 298
Study: 15860753

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 100 microg
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 500 microg
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Salmeterol 50 microg
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Combination therapy with 100 microg FP and salmeterol
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Salmeterol in combination with FP
Number of subjects: 7
Study: 12190841

Group type: EXPERIMENTAL
Intervention: E2 1 mg daily plus intermittent NGM 90 micro g (3 days off, 3 days on)
Number of subjects: 322

Group type: COMPARATOR
Intervention: E2 2 mg plus constant NETA 1 mg daily
Number of subjects: 322
Study: 10530636

Group type: EXPERIMENTAL
Intervention: Sertraline hydrochloride (50 to 150 mg/d)
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Desipramine hydrochloride (50 to 150 mg/d)
Number of subjects: 189

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 189
Study: 8615540

Group type: EXPERIMENTAL
Intervention: Phosphoroorganic or carbaminate intoxications (Ia)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ethylene glycol intoxication (Ib)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amanita phalloides poisoning (Id)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chronic active hepatitis (II)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Toxogonine in vitro test
Number of subjects: 0
Study: 2104090

Group type: EXPERIMENTAL
Intervention: 400 mg cimetidine b.d.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 800 mg cimetidine nocte
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 6988942

Group type: EXPERIMENTAL
Intervention: Trimipramine 25 mg nocte
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg nocte
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Cimetidine 200 mg 3 times a day and 400 mg nocte (standard dose)
Number of subjects: 95
Study: 30521044

Group type: EXPERIMENTAL
Intervention: Zinc combined with probiotics (Bifico)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Bifico (probiotics)
Number of subjects: 50
Study: 28118062

Group type: EXPERIMENTAL
Intervention: Taurine supplementation (500 mg three times per day for two weeks)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Taurine supplementation
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 26504842

Group type: EXPERIMENTAL
Intervention: Intervention group (diet and physical activity education and behavioural change techniques)
Number of subjects: 329

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 329
Study: 23392656

Group type: EXPERIMENTAL
Intervention: Activity in ventromedial prefrontal cortex (vmPFC) during choice and feedback
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Activity in dorsal anterior cingulate cortex (dACC) during choice and feedback
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: vmPFC, mid-cingulate, and posterior cingulate cortex activity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Feedback effects in vmPFC
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Feedback effects in dACC
Number of subjects: 0
Study: 21234528

Group type: EXPERIMENTAL
Intervention: Cytokinesis‐block micronucleus (CBMN) assay
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Chromosome aberration technique (CAT)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Comparison of CBMN assay and CAT
Number of subjects: 22
Study: 19233765

Group type: EXPERIMENTAL
Intervention: Intermittent antegrade blood cardioplegia with 300 mg of NAC
Number of subjects: 20

Group type: COMPARATOR
Intervention: Intermittent antegrade blood cardioplegia without NAC (control group)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both groups (with and without NAC)
Number of subjects: 20
Study: 17578983

Group type: EXPERIMENTAL
Intervention: Single injection group (droperidol 2.5 mg)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Continuous group (droperidol 1.25 mg/day)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Combined single (droperidol 1.25 mg) and continuous (droperidol 0.625 mg/day) group
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control group (no droperidol)
Number of subjects: 160
Study: 15884202

Group type: EXPERIMENTAL
Intervention: Health education and physical training (6 weeks education, 25 weeks training)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Health education and physical training
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 64
Study: 11831117

Group type: EXPERIMENTAL
Intervention: Ionic contrast medium Hypaque‐76 (n = 31)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Nonionic contrast medium Ultravist‐370 (n = 31)
Number of subjects: 62
Study: 10964861

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 635

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 635
Study: 8639722

Group type: COMPARATOR
Intervention: Standard enteral diet
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Enriched enteral diet (with arginine, RNA, and omega-3 fatty acids)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Total parenteral nutrition
Number of subjects: 60
Study: 1851578

Group type: EXPERIMENTAL
Intervention: Radiotherapy plus lonidamine
Number of subjects: 6

Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 6
Study: 6421083

Group type: EXPERIMENTAL
Intervention: Vaginal cream containing 0.5 mg estriol (OvestinR)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Vaginal suppositories containing 0.5 mg estriol (OvestinR)
Number of subjects: 30
Study: 30747707

Group type: EXPERIMENTAL
Intervention: Secondary long-term prophylaxis (PRO) with vWF/FVIII concentrates
Number of subjects: 19

Group type: COMPARATOR
Intervention: On-demand treatment (ODT) with vWF/FVIII concentrates
Number of subjects: 19
Study: 29437056

Group type: EXPERIMENTAL
Intervention: 1.5 g intra-articularly after closure of the wound
Number of subjects: 182

Group type: COMPARATOR
Intervention: Two doses of 10 mg/kg IV
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Both interventions (intra-articular and IV)
Number of subjects: 182
Study: 26323998

Group type: EXPERIMENTAL
Intervention: Focused Ultrasonography course
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control circumstances
Number of subjects: 31
Study: 23988395

Group type: COMPARATOR
Intervention: Short‐Term Executive Plus (STEP) program: 12 weeks (9h/wk) of group training in problem solving and emotional regulation and individual sessions of attention and compensatory strategies training.
Number of subjects: 98
Study: 22915083

Group type: EXPERIMENTAL
Intervention: Supportive relationship prime
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonsupportive relationship prime
Number of subjects: 0
Study: 20124114

Group type: EXPERIMENTAL
Intervention: 1.2-g/d omega-3 PUFA
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study: 18795194

Group type: EXPERIMENTAL
Intervention: Transference‐Focused Psychotherapy (TFP)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Dialectical Behavior Therapy (DBT)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Supportive Psychotherapy (SP)
Number of subjects: 90
Study: 15893433

Group type: EXPERIMENTAL
Intervention: Internet-based intervention
Number of subjects: 83

Group type: COMPARATOR
Intervention: Internet-based intervention + self-help book
Number of subjects: 83
Study: 11920412

Group type: EXPERIMENTAL
Intervention: Infliximab (5 mg/kg, intravenous loading dose at weeks 0, 2, and 6)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 40
Study: 10517731

Group type: EXPERIMENTAL
Intervention: Tirofiban plus heparin
Number of subjects: 1915

Group type: COMPARATOR
Intervention: Heparin alone
Number of subjects: 1915

Group type: EXPERIMENTAL
Intervention: Persistence of a thrombus
Number of subjects: 1915
Study: 7627447

Group type: EXPERIMENTAL
Intervention: Eye Movement Desensitization and Reprocessing (EMDR)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Relaxation Training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Biofeedback
Number of subjects: 0

Group type: COMPARATOR
Intervention: Inpatient treatment (control group)
Number of subjects: 0
Study: 2043997

Group type: EXPERIMENTAL
Intervention: Ultracaine (articaine HC1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Citanest (prilocaine HC1)
Number of subjects: 0
Study: 31164429

Group type: EXPERIMENTAL
Intervention: CPAP treatment
Number of subjects: 145

Group type: COMPARATOR
Intervention: No CPAP
Number of subjects: 145
Study: 30241679

Group type: EXPERIMENTAL
Intervention: Laser-activated irrigation (LAI) with an Er:YAG laser and a 600-μm tip over the canal entrance
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Laser-activated irrigation (LAI) with an Er:YAG laser and a conical 400-μm fiber tip in the canal entrance
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional needle irrigation (NI)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Manual-dynamic irrigation
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Ultrasonically activated irrigation using a size 20 Irrisafe
Number of subjects: 50
Study: 26026186

Group type: EXPERIMENTAL
Intervention: Telemedicine
Number of subjects: 103

Group type: COMPARATOR
Intervention: Telephone
Number of subjects: 103
Study: 24156616

Group type: EXPERIMENTAL
Intervention: AlcoholEdu for College
Number of subjects: 2400
Study: 22526273

Group type: EXPERIMENTAL
Intervention: Rabeprazole 10 mg daily
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg daily
Number of subjects: 261

Group type: COMPARATOR
Intervention: Gefarnate 50 mg twice daily
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: Rabeprazole (both dosages combined)
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: Rabeprazole
Number of subjects: 261
Study: 20107424

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy
Number of subjects: 13

Group type: COMPARATOR
Intervention: Surgery-alone
Number of subjects: 13
Study: 17624545

Group type: EXPERIMENTAL
Intervention: Resistance Exercise (RE)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Endurance Exercise (EE)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control (CEE)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control (CRE)
Number of subjects: 18
Study: 16142707

Group type: EXPERIMENTAL
Intervention: Sulfasalazine (SSZ)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 12126174

Group type: EXPERIMENTAL
Intervention: Active acustimulation of the Pericardium 6 (PC-6) point on the ventral surface of the wrist
Number of subjects: 27

Group type: COMPARATOR
Intervention: No acustimulation (control group)
Number of subjects: 27
Study: 10434980

Group type: EXPERIMENTAL
Intervention: HIV testing offered on a universal, voluntary basis
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Routine HIV testing recommended to pregnant women
Number of subjects: 29
Study: 7572825

Group type: EXPERIMENTAL
Intervention: Preventive, psychoeducational intervention program (13 weeks)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Wait-list control condition
Number of subjects: 51
Study: 1968728

Group type: EXPERIMENTAL
Intervention: Atracurium (A)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Vecuronium (V)
Number of subjects: 26
Study: 7438413

Group type: EXPERIMENTAL
Intervention: Flunisolide (200 micrograms/day)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 30412786

Group type: EXPERIMENTAL
Intervention: Intravenous tranexamic acid plus bilateral uterine artery ligation (BUAL)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Bilateral uterine artery ligation (BUAL) alone
Number of subjects: 62
Study: 27666722

Group type: EXPERIMENTAL
Intervention: Single GON block with 5 cc 1% lidocaine
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Three-stage GON block with 5 cc 1% lidocaine
Number of subjects: 105

Group type: COMPARATOR
Intervention: Triptan withdrawal only
Number of subjects: 105
Study: 26489022

Group type: EXPERIMENTAL
Intervention: High Intensity Interval Training (HIIT)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Moderate Intensity Training (MIT)
Number of subjects: 28
Study: 24480677

Group type: EXPERIMENTAL
Intervention: 1 mg tofacitinib
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: 5 mg tofacitinib
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: 15 mg tofacitinib
Number of subjects: 139

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 139